SecBot SecBot
SECBOTREPLAY Home › Report › STOK

STOK · Stoke Therapeutics' 2026 proxy statement details the election of three…

Stoke Therapeutics, Inc. · DEFA14A filed Apr 22, 2026 at 16:09 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Apr 22, 2026 at 16:09 ET

Stoke Therapeutics' 2026 proxy statement details the election of three Class I directors, ratification of auditors, and advisory approval of executive compensation. This filing is routine governance material, routine for a biotech company.

  • Election of Class I directors: G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D., and Julie Anne Smith
  • Ratification of Ernst & Young LLP as independent auditors for fiscal year 2026
  • Advisory vote on executive compensation

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access